Featuring perspectives from Dr Shirish M Gadgeel on the later-line management of metastatic squamous cell carcinoma of the lung.
Recent advances in the management of advanced non-small cell lung cancer (NSCLC) (0:00)
Case: A woman in her early 70s with metastatic squamous cell carcinoma (SCC) of the lung receives carboplatin/paclitaxel and pembrolizumab as first-line therapy on the KEYNOTE-021 trial (02:25)
Response to pembrolizumab and chemotherapy in advanced SCC of the lung (04:34)
Efficacy of pembrolizumab alone or in combination with chemotherapy for advanced NSCLC (07:41)
Choice of immune checkpoint inhibitor/chemotherapy regimen as first-line therapy for metastatic SCC of the lung (12:22)
Results of the Phase III CheckMate 227 trial evaluating nivolumab alone, with ipilimumab or with chemotherapy as first-line therapy for metastatic NSCLC (15:43)
Interim overall survival analysis of the Phase III IMpower110 study investigating atezolizumab versus platinum-based chemotherapy for metastatic NSCLC in the first-line setting (18:32)
Cancer site and adverse events induced by immune checkpoint inhibitors (20:05)
Genetic alterations in patients with SCC of the lung; rationale for targeting the ERBB signaling pathway (22:18)
Results of the Phase III LUX-Lung 8 trial of afatinib versus erlotinib as second-line treatment for advanced SCC of the lung (25:53)
Secondary analysis of LUX-Lung 8: Association of ERBB mutations with clinical outcomes among patients with afatinib- or erlotinib-treated SCC of the lung (28:04)
Role of HER2 mutations and HER2 amplification in patients with NSCLC; incidence of HER2 alterations in patients with SCC of the lung (30:14)
Targeting HER2 alterations with the tyrosine kinase inhibitors afatinib and dacomitinib in patients with NSCLC (34:15)
Efficacy of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201) in patients with NSCLC and HER2 alterations (36:11)
Activity of T-DM1 in patients with NSCLC and HER2 mutations (38:04)
Management of gastrointestinal side effects associated with afatinib (40:22)
Activity of afatinib in heavily pretreated ERBB2 mutation-positive advanced NSCLC (43:01)
Afatinib in patients with metastatic or recurrent lung cancer with HER2 mutations (45:15)
Case: A man in his early 80s develops metastases to the liver during treatment with durvalumab after chemoradiation therapy for Stage III SCC of the lung and is found to have FGFR1 amplification (47:15)
FGFR signaling as a target for NSCLC therapy; outcomes with the FGFR inhibitor AZD4547 in patients with metastatic SCC of the lung and FGFR alterations (51:04)
SWOG-S1400 Lung Cancer Master Protocol (Lung-MAP) — Biomarker-targeted therapy for patients with previously treated Stage IV SCC of the lung (56:02)
Case: A woman in her early 50s with ALK-rearranged metastatic lung adenocarcinoma experiences a dramatic response to crizotinib on the PROFILE 1014 study (1:02:39)
Response to ALK inhibitors for ALK-rearranged metastatic NSCLC (1:06:54)
Podden och tillhörande omslagsbild på den här sidan tillhör Dr Neil Love. Innehållet i podden är skapat av Dr Neil Love och inte av, eller tillsammans med, Poddtoppen.
